Exploring the Potential of Symmetric Exon Deletion to Treat Non-Ischemic Dilated Cardiomyopathy by Removing Frameshift Mutations in TTN .

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101551097 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4425 (Electronic) Linking ISSN: 20734425 NLM ISO Abbreviation: Genes (Basel) Subsets: MEDLINE

Original Publication: Basel : MDPI

Cardiomyopathy, Dilated*/genetics ; Connectin*/genetics ; Frameshift Mutation*; Exons/genetics ; Humans

Non-ischemic dilated cardiomyopathy (DCM) is one of the most frequent pathologies requiring cardiac transplants. Even though the etiology of this disease is complex, frameshift mutations in the giant sarcomeric protein Titin could explain up to 25% of the familial and 18% of the sporadic cases of DCM. Many studies have shown the potential of genome editing using CRISPR/Cas9 to correct truncating mutations in sarcomeric proteins and have established the grounds for myoediting. However, these therapies are still in an immature state, with only few studies showing an efficient treatment of cardiac diseases. This publication hypothesizes that the Titin ( TTN )-specific gene structure allows the application of myoediting approaches in a broad range of locations to reframe TTNtvvariants and to treat DCM patients. Additionally, to pave the way for the generation of efficient myoediting approaches for DCM, we screened and selected promising target locations in TTN . We conceptually explored the deletion of symmetric exons as a therapeutic approach to restore TTN 's reading frame in cases of frameshift mutations. We identified a set of 94 potential candidate exons of TTN that we consider particularly suitable for this therapeutic deletion. With this study, we aim to contribute to the development of new therapies to efficiently treat titinopathies and other diseases caused by mutations in genes encoding proteins with modular structures, e.g., Obscurin.

Hum Mol Genet. 2021 Jun 9;30(12):1131-1141. (PMID: 33438037)
Mol Ther. 2013 Aug;21(8):1551-8. (PMID: 23752313)
BMJ. 2019 May 2;365:l1570. (PMID: 31048310)
Ann Neurol. 2007 Apr;61(4):340-51. (PMID: 17444505)
PLoS One. 2017 Jun 1;12(6):e0178700. (PMID: 28570605)
Front Cardiovasc Med. 2016 Jul 21;3:21. (PMID: 27493940)
J Neuromuscul Dis. 2016 Aug 30;3(3):293-308. (PMID: 27854229)
Clin Pharmacol Ther. 2019 Jan;105(1):79-85. (PMID: 30415499)
Nat Biotechnol. 2016 Sep 08;34(9):933-941. (PMID: 27606440)
Sci Transl Med. 2021 Nov 03;13(618):eabd7287. (PMID: 34731015)
Hum Gene Ther. 2008 Dec;19(12):1359-68. (PMID: 18795839)
Am J Cardiol. 2012 Jun 1;109(11):1644-50. (PMID: 22475360)
Mol Biol Evol. 2004 Jun;21(6):1042-56. (PMID: 15014174)
J Cell Biol. 1988 May;106(5):1563-72. (PMID: 2453516)
Hum Gene Ther. 2015 Jul;26(7):443-51. (PMID: 26068008)
Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12705-10. (PMID: 26417073)
Circ Cardiovasc Genet. 2016 Oct;9(5):419-425. (PMID: 27625338)
Biochem Biophys Res Commun. 2007 Oct 19;362(2):281-7. (PMID: 17716621)
Nat Genet. 2017 Jan;49(1):46-53. (PMID: 27869827)
Tissue Eng Part A. 2019 May;25(9-10):725-735. (PMID: 30520705)
Int J Cardiol. 2017 Aug 15;241:379-386. (PMID: 28377185)
Circulation. 2022 Jan 18;145(3):194-205. (PMID: 34905694)
Cell Mol Life Sci. 2016 Aug;73(15):2959-68. (PMID: 26817461)
Wellcome Open Res. 2016 Nov 15;1:13. (PMID: 27976757)
Arch Med Sci. 2016 Apr 1;12(2):263-78. (PMID: 27186169)
Nucleic Acids Res. 2021 Jan 8;49(D1):D309-D318. (PMID: 32976589)
Science. 2016 Jan 22;351(6271):400-3. (PMID: 26721683)
F1000Res. 2017 Dec 20;6:2153. (PMID: 29333255)
Biochim Biophys Acta. 2016 Sep;1863(9):2333-44. (PMID: 27350235)
Sci Transl Med. 2015 Jan 14;7(270):270ra6. (PMID: 25589632)
Nat Rev Cardiol. 2013 Sep;10(9):531-47. (PMID: 23900355)
Hum Gene Ther. 2015 Jun;26(6):347-56. (PMID: 25760560)
Mol Ther Nucleic Acids. 2017 Jun 16;7:11-19. (PMID: 28624187)
Cell Stem Cell. 2016 Apr 7;18(4):533-40. (PMID: 26877224)
J Am Coll Cardiol. 2010 Oct 26;56(18):1493-502. (PMID: 20951326)
Sci Transl Med. 2021 Nov 03;13(618):eabd3079. (PMID: 34731013)
J Biomed Biotechnol. 2010;2010:753675. (PMID: 20339475)
Sci Adv. 2018 Jan 31;4(1):eaap9004. (PMID: 29404407)
Annu Rev Genomics Hum Genet. 2016 Aug 31;17:131-54. (PMID: 27216776)
Science. 2016 Jan 22;351(6271):407-411. (PMID: 26721686)
Circ Res. 2017 Oct 27;121(10):1168-1181. (PMID: 28851809)
Genes (Basel). 2022 Jan 28;13(2):. (PMID: 35205302)
Oncotarget. 2017 Jan 24;8(4):5647. (PMID: 28077794)
Lancet. 2017 Jul 22;390(10092):400-414. (PMID: 28190577)
Hum Mol Genet. 2014 Feb 15;23(4):980-91. (PMID: 24105469)
Circulation. 2017 May 9;135(19):1832-1847. (PMID: 28167635)
Nat Genet. 2002 Feb;30(2):205-9. (PMID: 11788825)
Sci Rep. 2018 Oct 24;8(1):15728. (PMID: 30356055)
Hum Genet. 2000 Nov;107(5):440-51. (PMID: 11140941)
Elife. 2015 Oct 16;4:e09406. (PMID: 26473617)
Circulation. 2013 Feb 26;127(8):938-44. (PMID: 23439446)
Nucleic Acids Res. 2005 Sep 28;33(17):5574-82. (PMID: 16192573)
Nat Rev Drug Discov. 2017 Feb;16(2):115-130. (PMID: 27980341)
PLoS One. 2015 Dec 23;10(12):e0145284. (PMID: 26701604)
Mol Cell. 2019 Feb 21;73(4):699-713.e6. (PMID: 30554945)
Development. 2016 Dec 15;143(24):4713-4722. (PMID: 27836965)
EMBO Mol Med. 2015 Mar 09;7(5):562-76. (PMID: 25759365)
Nat Rev Mol Cell Biol. 2012 Nov;13(11):713-26. (PMID: 23034453)
Mol Ther Nucleic Acids. 2017 Jun 16;7:31-41. (PMID: 28624206)
Annu Rev Physiol. 2018 Feb 10;80:389-411. (PMID: 29131758)
Biochem Biophys Res Commun. 2003 Oct 24;310(3):910-8. (PMID: 14550291)
Physiol Rev. 2009 Oct;89(4):1217-67. (PMID: 19789381)
Cell Res. 2016 Oct;26(10):1099-1111. (PMID: 27573176)
J Am Coll Cardiol. 2016 May 10;67(18):2161-2176. (PMID: 27151349)
Science. 2016 Jan 1;351(6268):84-8. (PMID: 26628643)
Front Physiol. 2019 Nov 28;10:1436. (PMID: 31849696)
Cell. 2014 Jun 5;157(6):1262-1278. (PMID: 24906146)
J Muscle Res Cell Motil. 2019 Jun;40(2):159-167. (PMID: 31147888)
Bioconjug Chem. 2017 Apr 19;28(4):880-884. (PMID: 28263568)
Nat Commun. 2017 Feb 21;8:14500. (PMID: 28220790)
Circ Res. 2021 Sep 3;129(6):602-616. (PMID: 34372664)
N Engl J Med. 2012 Feb 16;366(7):619-28. (PMID: 22335739)
Circ Res. 2017 Sep 15;121(7):711-721. (PMID: 28912178)
In Silico Biol. 2004;4(4):387-93. (PMID: 15217358)
Science. 2015 Aug 28;349(6251):982-6. (PMID: 26315439)
Biophys Rev. 2017 Jun;9(3):207-223. (PMID: 28510119)
Science. 2013 Feb 15;339(6121):819-23. (PMID: 23287718)
Science. 2016 Jan 22;351(6271):403-7. (PMID: 26721684)
Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):338-43. (PMID: 26719419)
Int J Mol Sci. 2020 Jan 22;21(3):. (PMID: 31979133)

Keywords: CRISPR/Cas9; OBSCN; Obscurin; TTN; Titin; exons; myoediting; symmetry

0 (Connectin)
0 (TTN protein, human)

Date Created: 20220624 Date Completed: 20220627 Latest Revision: 20220924

20240829

PMC9222585

10.3390/genes13061093

35741855